HIV / AIDS

“Patients deserve more than just viral suppression,” said Harmony Garges, MD, chief medical officer of ViiV Healthcare.

“We should test everybody,” said Charles Béguelin, noting that the vast majority of hepatitis D infections go undetected.

Here is an overview of highly anticipated HIV trial data ViiV Healthcare will share next week at the CROI 2023 conference.

Among male couples, HIV PrEP usage is suboptimal. Lingering stigma may be preventing men who have sex with men from using PrEP, even when in a relationship with an HIV-positive partner.

February 7 is National Black HIV/AIDS Awareness Day (#NBHAAD). In observance, we're recapping stories to raise awareness and work toward ending HIV/AIDS disparities in Black communities.

The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

Clinicians can make room for infrequent treatment options as patients enjoy their daily lives.

This therapy is the first of a new class of antiretrovirals, and it is indicated for people with multi-drug resistance, intolerance, or safety considerations.

A central portal to support clinical practice for patients with or at risk for HIV was launched.

Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.

A new CDC report highlights another health-related area where interruptions occurred due to the pandemic, but data suggests both improved rapidly.

Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Triumeq PD, the first dispersible single tablet regimen with dolutegravir, for children living with HIV.

For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the implications of recent data regarding the use of fostemsavir and ibalizumab.

The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.

Daniel R. Kuritzkes, MD, describes how the unique mechanism of lenacapavir allows clinicians to maintain viral inhibition over time.

Joseph Eron, MD, and Monica Gandhi, MD, MPH, describe the obstacles to treatment efficacy with the available treatment options.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, explore the relative pros and cons of various agents and drug classes that may be used for the treatment of multi-drug resistant HIV.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, share recommendations to improve pre-therapy resistance testing in community settings.

Read and watch the infectious disease trial data shared this week.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, review strategies for determining whether drug resistance is the primary reason for suboptimal treatment response or adherence.

Thought leaders discuss when and how to approach drug resistance and steps to ensure long-term treatment success.

Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.